金匮肾气丸辅治Ⅱ-Ⅲ期糖尿病肾病疗效观察

目的:观察金匮肾气丸辅治Ⅱ-Ⅲ期糖尿病肾病的临床疗效。方法:74例按照随机数字表法分为对照组与研究组各37例,两组均用达格列净和贝那普利治疗,研究组加用金匮肾气丸。结果:研究组总有效率与估算肾小球滤过率(eGFR)水平高于对照组(P<0.05),中医证候积分、血肌酐(SCR)、血尿素氮(BUN)、24h尿总量蛋白(TUP)和尿微量白蛋白/尿肌酐(UMA/UCR)以及空腹血糖(FBG)水平均低于对照组(P<0.05)。结论:金匮肾气丸辅治Ⅱ-Ⅲ期糖尿病肾病可提高疗效。

血清TAP、proGRP、cyfra21-1与Ⅲ~Ⅳ期NSCLC新辅助化疗疗效及预后的关系

目的探讨血清肿瘤异常蛋白(TAP)、胃泌素释放肽前体(proGRP)、细胞角蛋白19片段(cyfra21-1)与Ⅲ~Ⅳ期非小细胞肺癌(NSCLC)新辅助化疗(NCT)疗效及预后的关系。方法选取100例Ⅲ~Ⅳ期NSCLC患者为研究对象,所有患者均采用NCT治疗,根据疗效将患者分为有效组和无效组,比较不同疗效患者化疗前后TAP、proGRP、cyfra21-1水平,分析化疗后TAP、proGRP、cyfra21-1水平对NSCLC患者NCT疗效的评估价值。所有患者均随访1年,分析化疗后TAP、proGRP、cyfra21-1表达水平与预后的关系。结果化疗后,有效组TAP、proGRP、cyfra21-1水平低于无效组(P<0.05)。ROC曲线结果显示,TAP评估NSCLC患者NCT疗效的AUC和截点值分别为0.739、178.18μm 2,proGRP评估NSCLC患者NCT疗效的AUC和截点值分别为0.810、52.21 ng/L,cyfra21-1评估NSCLC患者NCT疗效的AUC和截点值分别为0.775、7.70μmol/L,联合评估NSCLC患者NCT疗效的AUC为0.913,高于单项诊断(P<0.05)。TAP、proGRP、cyfra21-1高表达患者的1年生存率均低于低表达患者(P<0.05)。结论TAP、proGRP、cyfra21-1联合评估Ⅲ~Ⅳ期NSCLC患者NCT疗效具有较高价值,且其均与NSCLC患者预后密切相关。

Prognostic and predictive significance of MSI in stages Ⅱ/Ⅲ colon cancer

In colon cancer,classic disease staging remains the key prognosis and treatment determinant.Although adjuvant chemotherapy has an established role in stageⅢcolon cancer patients,in stageⅡit is still a subject of controversy due to its restriction to a small subgroup of patients with high-risk histopathologic features.Patients with stageⅡtumors form a highly heterogeneous group,with five-year relative overall survival rates ranging from 87.5%(ⅡA)to 58.4%(ⅡC).Identifying those for whom adjuvant chemotherapy would be appropriate and necessary has been challenging,and prognostic markers which could serve in the selection of patients more likely to recur or benefit from adjuvant chemotherapy are eagerly needed.The stronger candidate in this category seems to be microsatellite instability(MSI).The recently reported European Society for Medical Oncology guidelines suggest that MSI should be evaluated in stageⅡcolorectal cancer patients in order to contribute in treatment decisionmaking regarding chemotherapy administration.Thehypothetical predictive role of MSI regarding its response to 5-fluorouracil-based adjuvant chemotherapy has proven a much more difficult issue to address.Almost every possible relation between MSI and chemotherapy outcome has been described in the adjuvant colon cancer setting in the international literature,and the matter is far from being settled.In this current report we critically evaluate the prognostic and predictive impact of MSI status in patients with stageⅡand stageⅢcolon cancer patients.

Macroscopic appearance of TypeⅣand giant Type Ⅲ is a high risk for a poor prognosis in pathological stage Ⅱ/Ⅲ advanced gastric cancer with postoperative adjuvant chemotherapy

AIM To evaluate whether a high risk macroscopic appearance(Type Ⅳ and giant Type Ⅲ) is associated with a dismal prognosis after curative surgery, because its prognostic relevance remains elusive in pathological stage Ⅱ/Ⅲ(p Stage Ⅱ/Ⅲ) gastric cancer.METHODS One hundred and seventy-two advanced gastric cancer(defined as pT2 or beyond) patients with p Stage Ⅱ/Ⅲ who underwent curative surgery plus adjuvant S1 chemotherapy were evaluated, and the prognostic relevance of a high-risk macroscopic appearance was examined. RESULTS Advanced gastric cancers with a high-risk macroscopic appearance were retrospectively identified by preoperative recorded images. A high-risk macroscopic appearance showed a significantly worse relapse free survival(RFS)(35.7%) and overall survival(OS)(34%) than an average risk appearance(P = 0.0003 and P < 0.0001, respectively). A high-risk macroscopic appearance was significantly associated with the 13^(th) Japanese Gastric Cancer Association(JGCA) pT(P = 0.01), but not with the 13^(th) JGCA pN. On univariate analysis for RFS and OS, prognostic factors included 13^(th) JGCA p Stage(P < 0.0001)and other clinicopathological factors including macroscopic appearance. A multivariate Cox proportional hazards model for univariate prognostic factors identified highrisk macroscopic appearance(P = 0.036, HR = 2.29 for RFS and P = 0.021, HR = 2.74 for OS) as an independent prognostic indicator. CONCLUSION A high-risk macroscopic appearance was associated with a poor prognosis, and it could be a prognostic factor independent of 13^(th) JGCA stage in p Stage Ⅱ/Ⅲ advanced gastric cancer.

Stage Ⅲ should be subclassified into Stage ⅢA and ⅢB in the American Joint Committee on Cancer(8^(th) Edition) staging system for pancreatic cancer

AIM To ascertain the prognostic role of the T4 and N2 category in stage Ⅲ pancreatic cancer according to the 8 th edition of the American Joint Committee on Cancer(AJCC) classification.METHODS Patients were collected from the Surveillance Epidemiology and End Results(SEER) database(2004-2013) and were divided into three groups: T(1-3)N2, T4 N(0-1), and T4 N2. Overall survival(OS) and disease-specific survival(DSS) of patients were evaluated by the Kaplan-Meier method. RESULTS For the first time, we found a significant difference in OS and DSS between T(1-3)N2/T4 N(0-1) and T4 N2 butnot between T(1-3)N2 and T4 N(0-1). A higher grading correlated with a worse prognosis in the T(1-3)N2 and T4 N2 groups.CONCLUSION Patients with stage T4 N2 had a worse prognosis than those with stage T(1-3)N2/T4 N(0-1) in the 8 th edition AJCC staging system for pancreatic cancer. We recommend that stage Ⅲ should be subclassified into stage ⅢA [T(1-3)N2/T4 N(0-1)] and stage ⅢB(T4 N2).

Effect of TCM Combined with Chemotherapy on Immune Function and Quality of Life of Patients with Non-small Cell Lung Cancer inStage Ⅲ-Ⅳ

Objective: To observe and compare the effect of traditional Chinese medicine (TCM) combined with chemotherapy (CT) on immune function and quality of life (QOL)of patients with non-small cell lung cancer (NSCLC) in stage Ⅲ-Ⅳ. Methods: One hundred cases with stage Ⅲ-Ⅳ NSCLC were randomly divided into two groups. The treated group (n=50) received CT combined with TCM, and the control group received CT alone. The percentage of T lymphocyte subset in peripheral blood and the change of natural killer (NK) cell count were observed after treatment. The QOL and tolerance of CT were also compared between the two groups after treatment. Results: In the treated group, CD3 cell count, CD4 cell count, CD4/ CDg ratio and NK cell activity were higher than those in control group, while CD8 cell count in the treated group was lower than that in the control group (P<0.05), and QOL and tolerance of CT in the treated group were also better (P<0.05). Conclusion: TCM combined with CT could raise the patients' ability in tolerating CT in stage Ⅲ-ⅣNSCLC.

Unresectable stage Ⅲ non-small-cell lung cancer: Have we made any progress?

Lung cancer is responsible for the most cancer deaths worldwide with an incidence that is still rising. One third of patients have unresectable stage ⅢA or stage ⅢB disease. The standard of care for locally advanceddisease in patients with good performance status consists of combined modality therapy in particular concurrent chemoradiotherapy. But despite a lot of efforts done in the past, local control and survival of patients with unresectable stage Ⅲ non-small-cell lung cancer(NSCLC) remains poor. Improving outcomes for patients with unresectable stage Ⅲ NSCLC has therefore been an area of ongoing research. Research has focused on improving systemic therapy, improving radiation therapy or adding a maintenance therapy to consolidate the initial therapy. Also implementation of newer targeted therapies and immunotherapy has been investigated as well as the option of prophylactic cranial irradiation. This article reviews the latest literature on improving local control and preventing distant metastases. It seems that we have reached a plateau with conventional chemotherapy. Radiotherapy dose escalation did not improve outcome although increasing radiation dose-intensity with new radiotherapy techniques and the use of newer agents, e.g., immunotherapy might be promising. In the future well-designed clinical trials are necessary to prove those promising results.

Role of radiation therapy in the management of stage Ⅲ non-small cell lung cancers: current status and controversies

The treatment of stage Ⅲ non-small cell lung cancer(NSCLC) consisting of the heterogeneous stage subsets remains a challenge. Overall, it has been gradually recognized that radiation therapy(RT) plays a crucial role in the management of stage Ⅲ NSCLC. One superior sulcus tumors are the subset for which the trimodality treatments are clearly preferred. One subset of stage Ⅲ NSCLC has a minimal disease burden with microscopic p N2 disease or with discrete p N2 involvement identified preoperatively, thus technically could undergo a surgical resection. For the incidentally found p N2 disease after complete surgery(ⅢA-1, ⅢA-2), the value of postoperative radiotherapy(PORT) has been recognized by a reassessment based on new data. However, doubt persists regarding how to define the clinical target volume for PORT. For the discrete p N2 involvement identified preoperatively(a selected part of ⅢA-3), induction chemoradiation therapy(CRT) before surgery may yield a survival advantage, although the phase Ⅲ randomized trials in this issue are not conclusive. The other major subset of stage Ⅲ NSCLC is the infiltrative stage Ⅲ NSCLC with N2 or N3 nodal disease(ⅢA-3, ⅢA-4, and ⅢB), for which concurrent CRT is considered as the current standard of care. The potential role of radiation dose escalation/acceleration has been proposed; however, the optimal dose fractionation remains an important unresolved question. Additionally, the role of prophylactic cranial irradiation for stage Ⅲ patients with high risk of brain metastasis is worth of further assessment. Moreover, how to integrate molecular targeted therapy with RT, as well as whether they had a role in stage Ⅲ diseases, are other controversies actively under study in ongoing trials. This review specifically describes the updated role of RT in multimodal approach to treat stage Ⅲ NSCLC and the controversies regarding these results in various situations.

Bushen Huoxue method combined with ACEI/ARB in treating diabetic kidney disease (stage Ⅲ):A meta-analysis and trial sequential analysis

Objective:To evaluate the efficiency of Bushen Huoxue method with ACEI/ARB in treating diabetic kidney disease(stageⅢ).Methods:A total of 8 major electronic databases(CNKI,WanFang,VIP,Sinomed,Pubmed,Embase,Cochrane Liberary,Web of Science)were retrieved since the establishment of the database to October 9,2019.Two reviewers extracted data,and assessed the methodological quality of the included studies.The analysis was made by Stata 15.0 and TSA 0.9 softwares.Results:A total of 10 RCT studies were obtained,including 711 patients with diabetic kidney disease of stageⅢ.Meta-analysis showed that the method of Bushen Huoxue with ACEI/ARB could reduce UAER[WMD=-31.24,95%CI(-42.98,-19.51)],β2-GM[WMD=-92.95,95%CI(-166.05,-19.85)],LDL-C[WMD=-0.19,95%CI(0.19,-0.30)].However,there were no significant effect for HbAlc[WMD=-0.08,95%CI(-0.17,-0.00)],Scr[WMD=-12.96,95%CI(-39.82,13.90)],BUN[WMD=-0.14,95%CI(-0.44,0.17)].The result of TSA indicated that the method of Bushen Huoxue with ACEI/ARB was effective in the treatment of diabetic kidney disease of stageⅢ.Conclusion:The study show that the method of Bushen Huoxue with ACEI/ARB can reduce urinary protein,renal tubular injury and LDL-C in patients with diabetic kidney disease of stageⅢ,and had no effect on HbAlc and renal function.But the conclusion of this study needs further research of high quality.

Yiqi Huoxue Decoction in the treatment of Qi and yin deficiency and stasis type diabetic nephropathy in stageⅢ and its effect on VEGF and TGF-β1

Objective:To observe the efficacy of Yiqi Huoxue Decoction in the treatment of patients with diabetic nephropathy(DN)stageⅢwith qi and yin deficiency and stasis and its effects on vascular endothelial growth factor(VEGF)and transforming growth factor-β(TGF-β1).Methods:Sixty patients with stage DN of Qi-yin deficiency and stasis type DN who were treated in the Endocrinology Department of the Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine from September 2018 to December 2019 were selected as the research subjects.The remainder method was used to divide them into 30 cases in the observation group and 30 cases in the control group.Patients in both groups were referred to the guidelines and expert consensus for general treatment of DN(hypogl-ycemic,antihypertensive,lipid-lowering,etc.).The control group was given pancreatic kallikrein enteric-coated tablets orally once,120U,3 times a day,and the observation group was given The traditional Chinese medicine Yiqi Huoxue Decoction was taken orally,one dose daily,twice a day in the morning and evening;the two groups intervened continuously for 8 weeks.Detect blood FPG,PBG,HbA1c,β2-MG,BUN,SCr,VEGF,TGF-β1,and urine mALB and UACR levels before and after treatment,and calculate eGFR before and after treatment in both groups;observe changes in TCM syndrome scores in the two groups,Compare its clinical efficacy.Results:After 8 weeks of treatment,the total clinical effective rate of patients in the observation group was 93.3%,which was significantly different from the control group of 76.6%(P<0.05);the TCM syndrome scores in the observation group were significantly lower than those before treatment and in the control group(P<0.05);The levels of FPG,HbA1c,PPG,mALB,β2-MG,UACR,VEGF,and TGF-β1 in the observation group were significantly lower than those in the control group,with significant differences(P<0.05).The levels of SCr and BUN in the observation group were significantly lower.Compared with before treatment,eGFR increased,but there was no signi-ficant difference(P>0.05).Conclusion:Yiqi Huoxue Decoction for the treatment of patients with DN typeⅢqi-yin deficiency and stasis type,not only helps to lower blood sugar levels,improve TCM syndromes,but also can reduce early renal damage,reduce urine albumin,and delay kidney function It may be further worsened and has better safety.The mechanism may be related to reducing the levels of VEGF and TGF-β1,thereby delaying the fibrosis of tubulointerstitial scar and inhibi-ting glomerular capillary sclerosis.

Ⅲ期非小细胞肺癌病人新辅助化疗联合免疫治疗后无病生存的影响因素分析

目的探讨Ⅲ期非小细胞肺癌(NSCLC)病人新辅助化疗联合免疫治疗后无病生存的影响因素。方法我院2014年5月~2019年5月接受新辅助化疗联合免疫治疗后行根治术的Ⅲ期NSCLC病人200例,在新辅助化疗联合免疫治疗后随访3年,根据3年无病生存情况分为无病生存组(76例)及非无病生存组(124例),采用Kaplan-Meier法分析无病生存期(DFS),采用Cox回归模型分析影响NSCLC新辅助化疗联合免疫治疗后行根治术病人无病生存的因素。结果200例病人3年无病生存76例,无病生存率为38.00%,中位DFS为21个月。无病生存组与非无病生存组吸烟史、分化程度、肿瘤直径、EGFR基因突变、ALK基因表达、新辅助化疗联合免疫治疗的疗效及术后辅助化疗等比较,差异有统计学意义(P<0.05)。Cox回归模型分析显示,吸烟史(OR=2.016,P=0.004)、低分化(OR=2.125,P=0.001)、肿瘤直径>3 cm(OR=1.958,P=0.007)、EGFR基因突变(OR=2.305,P=0.002)、ALK基因阳性表达(OR=2.450,P=0.004)、新辅助化疗联合免疫治疗后未缓解(OR=1.820,P=0.005)均为新辅助化疗联合免疫治疗后行NSCLC根治术病人无病生存的危险因素,术后辅助化疗(OR=1.728,P=0.006)为新辅助化疗联合免疫治疗后行NSCLC根治术病人无病生存的保护因素。结论NSCLC新辅助化疗联合免疫治疗后行根治术病人无病生存与吸烟史、分化程度、肿瘤直径、EGFR基因突变、ALK基因表达、新辅助化疗联合免疫治疗的疗效及术后辅助化疗等因素有关。

The famous Chinese medicine doctor Xue Jing-Dong Taohong Siwu Decoction cured 1 case of primary liver cancer stage Ⅲa

Primary liver cancer is the most common malignant tumor of the liver.Surgery,intervention,radiotherapy,and chemotherapy are the main treatment methods in the early stage,and the basic principles of post-treatment are palliative treatment and symptomatic treatment.Xue Jing-Dong,a famous Chinese doctor,started from the etiology and pathogenesis of liver cancer,used the methods of promoting blood circulation to remove blood stasis,nourishing blood and replenishing liver,and applied Taohong Siwu Decoction based on long-term clinical experience to cure 1 case of primary liver cancer stage Ⅲa in two years.The patient’s survival period can be prolonged and the quality of life can be improved.The author begins with the diagnosis of stage Ⅲa liver cancer,western medicine treatment methods,and previous treatment experience of traditional Chinese medicine,and briefly describes the diagnosis and treatment of this patient.

舒肝宁注射液对晚期血吸虫病肝纤维化患者HA,Ⅳ-C,LN,PC-Ⅲ水平的影响

目的分析舒肝宁注射液对晚期血吸虫病肝纤维化患者HA、Ⅳ-C、LN、PC-Ⅲ水平的影响。方法以住院部2020年8月-2022年6月收治的晚期血吸虫病肝纤维化患者50例为研究对象,采用抛硬币的方式将患者分为对照组(25例患者,行常规治疗)和观察组(25例患者,行常规治疗+舒肝宁注射液治疗),对比两组患者的治疗结果(肝纤维化水平、肝功能指标以及炎性因子水平)。结果观察组患者治疗后HA、Ⅳ-C、LN、PC-Ⅲ水平均低于对照组患者,观察组患者治疗后ALT、AST、TBIL均低于对照组,ALB高于对照组,护理前组间(P>0.05),护理前后组内(P<0.05)。观察组患者治疗后炎性因子(CRP、PCT、IL-6)水平明显更低,差异存在统计学意义(P<0.05),观察组患者的不良反应发生率(12.00%)与对照组(8.00%)之间差异不显著(P>0.05)。结论舒肝宁注射液对晚期血吸虫病肝纤维化患者的治疗效果较好,患者治疗后HA、Ⅳ-C、LN、PC-Ⅲ水平更低,炎性因子水平更低。该治疗方式的综合应用价值高,值得推广使用。

HkV和HRCT检查在职业性尘肺病诊断中的价值

目的探究高千伏胸片(HkV)和高分辨率计算机体层X线摄影术(HRCT)检查在职业性尘肺病诊断中的临床应用价值。方法回顾性分析133例进行职业病诊断的尘肺病患者资料,患者均接受HkV和HRCT检查,以临床病理检查为金标准,比较HkV和HRCT对尘肺患者肺部阴影的显示情况、图片质量、分期诊断符合率及尘肺合并症的检出情况。结果HRCT对肺部P影、小阴影检出率高于HkV(P<0.05),两组大阴影检出率比较,差异无统计学意义(P>0.05);HRCT检查图像质量有效率高于HkV检查(P<0.05);HRCT诊断总准确率高于HkV诊断(P<0.05);HRCT对肺部感染、肺气肿、胸膜增厚、气胸的检出率高于HkV(P<0.05),HRCT与HkV对肺结核、肺大泡检出率差异无统计学意义(P>0.05)。结论HRCT检查对职业性尘肺病患者肺部阴影、临床分期及合并症的诊断效果高于HkV,图片质量更高。

133例Ⅲ期鼻咽癌调强放疗的疗效及不良反应分析

背景与目的:调强放疗(intensity-modulated radiation therapy,IMRT)是最大限度提高肿瘤靶区照射剂量的同时明显减少周围正常组织的剂量的放疗技术,调强放疗联合化疗治疗局部晚期鼻咽癌取得了较好的疗效,如何在此基础上进一步提高疗效成为肿瘤学者共同关注的话题。鼻咽癌分期不同,疗效不同,同一分期各亚组间疗效有无差别,尚有待研究。通过回顾性分析临床Ⅲ期鼻咽癌各亚组间调强放疗联合化疗的疗效,探讨进一步提高疗效的方法。方法:对我院2003年1月—2006年6月期间收治的133例临床Ⅲ期鼻咽癌患者进行分析,根据AJCC 2002分期,其中T3N07例(5.3%),T3N139例(29.3%),T2N248例(36.1%),T3N239例(29.3%)。所有患者均完成调强放疗,124例患者行诱导化疗,其中24例患者行同期化疗,33例患者行辅助化疗。结果:全组5年局部控制率、无远处转移生存率、无瘤生存率和总生存率分别为:90.9%、89.9%、82.5%和83.4%。T2、T3期患者5年局部控制率分别为93.1%、89.4%(χ2=0.407,P=0.524),无远处转移生存率分别为91.2%、89.3%(χ2=0.152,P=0.697),无瘤生存率分别为86.5%、80.0%(χ2=0.899,P=0.343),总生存率分别为81.1%、84.7%(χ2=0.311,P=0.577)。N0-1、N2期患者5年局部控制率分别为91.1%、90.9%(χ2=0.007,P=0.933),无远处转移生存率分别为97.8%、85.8%(χ2=4.69,P=0.030),无瘤生存率分别为88.9%、79.2%(χ2=1.746,P=0.183 6),总生存率分别为93.5%、78.1%(χ2=5.052,P=0.025)。辅助化疗对IMRTⅢ期鼻咽癌未能获益,但3、4级毒性不良反应明显增加(48%vs 27.6%,P<0.005)。结论:对临床Ⅲ期鼻咽癌患者,IMRT联合化疗可以取得较好的疗效,N0-1期较N2期患者有较高的总生存率和无远处转移生存率,进一步提高IMRTⅢ期鼻咽癌疗效还需寻找更有效的化疗药物、靶向药物及更合理的联合治疗方案。

福寿螺体内广州管圆线虫Ⅲ期幼虫的形态学观察

目的观察福寿螺体内广州管圆线虫Ⅲ期幼虫的形态学特征。方法实验室培养的广州管圆线虫Ⅰ期幼虫感染禁食24h的福寿螺,61d解剖,取其肺囊和足肌,常规制作石蜡切片,观察其Ⅲ期幼虫外部形态和内部结构。结果Ⅲ期幼虫虫体卷曲,头部圆钝,咽管始于头部顶端的口孔,在咽肠连接处与肠管连接,尾部尖,肛管清晰。幼虫皮层为伊红染色,皮层外有一层无色透明的鞘膜。部分虫体尾部出现圆柱体,有些幼虫体内出现亚腹腺、很短的双管子宫等Ⅳ期幼虫早期特征。结论广州管圆线虫Ⅲ期幼虫的形态学特征清晰,对预防广州管圆线虫病流行有一定意义。

影响Ⅲ期结直肠癌预后的相关因素分析

目的总结Ⅲ期结直肠癌病例的临床病理特点、术后治疗特点及生存规律。方法回顾性分析了2005年1月至2008年12月在中国人民解放军总医院接受根治性手术治疗及术后辅助化疗的433例Ⅲ期结直肠癌患者的临床资料,总结了其临床病理特征、治疗特点及与生存预后的关系。结果 433例Ⅲ期结直肠癌患者的平均无疾病生存时间为(72.37±2.11)个月,中位无疾病生存时间未达到,1、3、5年无疾病生存率分别为86.8%、77.9%、57.0%。平均总生存时间为(79.91±2.02)个月,中位总生存时间未达到,1、3、5年总生存率分别为91.5%、75.1%、63.3%。COX多因素生存分析结果显示,术前肠梗阻、术后并发症、肿瘤部位、切缘阳性、神经浸润、脉管癌栓、肿瘤淋巴结转移(TNM)分期、淋巴结转移比率、辅助化疗方案、化疗持续时间等因素均为影响无疾病生存和总生存的独立预后因素。FOLFOX和XELOX方案与患者年龄、是否术后并发症、肿瘤部位及化疗持续时间具有明显相关性。结论术后并发症、肿瘤部位、TNM分期、切缘阳性等临床病理因素是Ⅲ期结直肠癌的独立预后因素。FOLFOX和XELOX方案可显著改善患者预后,化疗维持时间较长者治疗效果好。

Ⅲ期肺癌手术治疗生存率的分析

全组共1055例Ⅲ期肺癌手术切除,5、10年生存率分别为22.1％和15.3％,T_3N_0M_0预后好,5、10年生存率分别为41％和29.9％,虽N_2组预后较差,但是5,10年生存率仍有15.7％和9.1％,优于其它疗法。我们认为对纵隔淋巴结转移数少,及手术技术允许的N_2可以切除,但对食道旁、肺下韧带及隆突下淋巴结转移的手术应从严。Ⅲ期小细胞肺癌的长期生存率虽低,但和以往相比有所提高,可能和近年开展多方法学治疗有关,生存3年无病,可望根除。腺癌术后3年生存率仍不断下降,10年生存率仅为5年之半数,提示重视于血道、淋巴道内微转移灶之存在的重要性。

健脾消积口服液结合西药治疗Ⅱ、Ⅲ期肝癌40例的临床观察

目的:探讨健脾消积口服液结合西药治疗Ⅱ、Ⅲ期肝癌的临床疗效。方法:将75例Ⅱ、Ⅲ期肝癌患者按数字表法随机分为治疗组(40例)与对照组(35例),两组患者均采用相同的西药疗法,治疗组同时加用健脾消积口服液治疗。观察近期疗效、生存质量、中医证候变化、免疫学等指标变化。结果:治疗组与对照组完全缓解率分别为5％、0,稳定分别为62.5％、37.1％;生存质量:总改善率分别为47.5％、25.7％;证候改善率分别为80.0％、54.3％,两组间比较,差异均有显著性(P<0.01)。两组治疗前T淋巴细胞亚群比较差异无显著性,治疗组治疗后与治疗前比较,除CD_8外,CD_3、C_3D和CD_4。/CD_8比值改善,差异均有显著性(P<0.05或P<0.01),且优于对照组治疗后(P<0.05或P<0.01)。结论:健脾消积口服液可提高Ⅱ、Ⅲ期肝癌患者的生存质量,延长生存时间,并有提高细胞免疫功能的作用。

Ⅲ期结肠癌患者预后因素分析和术前对预后评估的探索

目的探讨Ⅲ期结肠癌的预后因素及术前预后评估的可行性。方法回顾性分析2004年1月至2008年6月间北京肿瘤医院外科手术治疗的Ⅲ期结肠癌患者临床病理资料,分析结肠癌的预后因素。对可能影响患者生存的因素进行单因素和Cox多因素模型分析。结果 (1)全部Ⅲ期患者3年无病生存率为63.4%;(2)单因素分析发现术前血清CEA水平>5 ng/ml、肿瘤分化程度低、肿瘤直径≥5 cm、更高的N分期、TNM分期和脉管癌栓(P<0.05)是影响Ⅲ期患者预后的因素;(3)多因素回归分析术前血清CEA水平(P=0.000,RR=2.832,1.755～6.023),N分期(P=0.001,RR=1.456,1.522～4.984),肿瘤直径≥5 cm(P=0.015,RR=1.663,1.155～3.871)是Ⅲ期患者生存的独立预后危险因素。结论根据术前血清CEA水平、肿瘤直径≥5 cm和更高N分期,可以对具有预后不良因素的Ⅲ期结肠癌患者进行更准确的风险分层,应针对Ⅲ期高危患者进行更积极的术前新辅助治疗以及更加密切的术后随访。